AKRO Akero Therapeutics

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at . Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at  and follow us on  and  for more information.

Investor Contact:

Christina Tartaglia

Precision AQ

332.322.7430

Media Contact:

Peg Rusconi

617.910.6217



EN
07/05/2025

Underlying

AKROAkero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akero Therapeutics

 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare C...

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at...

May 7, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at...

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two oral presentations and an upcoming poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, 2025, in Amsterdam, the Netherlands. Details for the presentations are as fol...

April 30, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial...

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update -- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH -- -- Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 --...

February 28, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Announces Closing of Upsized Public Offering of Com...

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering price of $48.00 per sh...

January 30, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Announces Pricing of Upsized Public Offering of Com...

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at a public offering price of $48.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants ...

January 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch